Biomarkers in the early diagnosis and treatment of cancer
Article Sidebar
Main Article Content
Abstract
In this paper points up the importance of biomarkers in the biomedical area for the development of technologies that allow early diagnosis and treatment of diseases such as cancer. Three of the biomarkers for cancer that have been shown to be effective for its treatment are highlighted: the prostate specific antigen (PSA), which is of utmost importance when determining recurrences of prostate cancer and evaluating the response to treatment, micro RNA (miRNA), which is altered in cancer cells, and the hormone β-HCG. The latter can be used as a tumor marker for various types of cancer and it has been determined that this hormone can act as an inhibitor of apoptosis and stimulate the growth of cellular cancers. Furthermore, there is a direct relationship between the concentration of β-HCG and the aggressiveness of the cancer.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores conservan los derechos de autor y ceden a la revista el derecho de la primera publicación y pueda editarlo, reproducirlo, distribuirlo, exhibirlo y comunicarlo en el país y en el extranjero mediante medios impresos y electrónicos. Asimismo, asumen el compromiso sobre cualquier litigio o reclamación relacionada con derechos de propiedad intelectual, exonerando de responsabilidad a la Editorial Tecnológica de Costa Rica. Además, se establece que los autores pueden realizar otros acuerdos contractuales independientes y adicionales para la distribución no exclusiva de la versión del artículo publicado en esta revista (p. ej., incluirlo en un repositorio institucional o publicarlo en un libro) siempre que indiquen claramente que el trabajo se publicó por primera vez en esta revista.
References
F. Islami, A. Goding Sauer, K.D. Miller, R.L. Siegel, S.A. Fedewa, E.J. Jacobs, et al. “Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States”. CA: A Cancer Journal for Clinicians. vol. 68, no.1, pp: 31–54, 2018
X. Wang, K.E. Kaczor-Urbanowicz, D.T.W. Wong, “Salivary biomarkers in cancer detection”. Medical Oncology. Humana Press Inc., vol. 34, 2017.
R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, “Cancer Statistics, 2021”. CA: A Cancer Journal for Clinicians. vol. 71, no. 1, pp: 7–33, 2021.
R. Mayeux, “Biomarkers: Potential Uses and Limitations”. The Journal of the American Society for Experimental NeuroTherapeutics, vol. 1, no. 2, pp: 182-188, 2004.
G. Palacios, R. Pedrero-Chamizo, N. Palacios, B. Maroto-Sánchez, S. Aznar, M. González-Gross, “Biomarcadores de la actividad física y del deporte”. Rev Esp Nutr Comunitaria. vol. 21, pp: 235–42, 2015.
V. Arango, S. Sandra, “Biomarcadores para la evaluación de riesgo”. Revista Facultad Nacional de Salud Pública, vol. 30, no. 1, pp:75–82, 2012.
M. Verma, S. Rosenfeld, “Challenges for Biomarkers in Cancer Detection”. Annals of The New York Academy of Sciences. vol. 1022, pp: 9–16, 2004.
S. Sethi, S. Ali, P.A. Philip, F.H. Sarkar, “Clinical advances in molecular biomarkers for cancer diagnosis and therapy”. International Journal of Molecular Sciences, vol. 14, pp. 71–84, 2013.
J. K. Aronson and R. E. Ferner, “Biomarkers—A General Review,” Current Protocols in Pharmacology, vol. 76, no. 1, 2017. doi: 10.1002/cpph.19.
J. L. da Silva, N. C. Cardoso Nunes, P. Izetti, G. G. de Mesquita, y A. C. de Melo, “Triple negative breast cancer: A thorough review of biomarkers,” Critical Reviews in Oncology/Hematology, vol. 145, p. 102855, 2020. doi: 10.1016/j.critrevonc.2019.102855.
K. Buder-Bakhaya and J. C. Hassel, “Biomarkers for Clinical Benefit of Immne Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond,” Frontiers in Immunology, vol. 9, 2018, doi: 10.3389/fimmu.2018.01474.
X. Filella y L. Foj, “Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers”. Int J Mol Sci, vol. 17, no. 11, pp. 1784, Oct. 2016. doi: http://doi.org/10.3390/ijms17111784
H. Lilja, J. Oldbring, G. Rannevik y C. Laurell, “Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen”. J Clin Invest, vol. 80, no. 2, pp. 281-285, 1987. doi: 10.1172 / JCI113070.
M. B. Gretzer y A. W. Partin, “PSA markers in prostate cancer detection”. Urol Clin North Am, vol. 30, no. 4, pp. 677-686, Nov. 2003. doi: 10.1016 / s0094-0143 (03) 00057-0.
U. H. Stenman, J. Leinonen, H. Alfthan, S. Rannikko, K. Tuhkanen y O.A. Alfthan, “Complex between Prostate-specific Antigen and α1-Antichymotrypsin Is the Major Form of Prostate-specific Antigen in Serum of Patients with Prostatic Cancer: Assay of the Complex Improves Clinical Sensitivity for Cancer”. Cancer Res, vo. 51, no. 1, 1991.
S. P. Balk, Y. J. Ko y G. J. Bubley, “Biology of Prostate-Specific Antigen”. J Clin Oncol, vol. 21, no. 2, pp. 383-91, Sep. 2016. doi: 10.1200 / JCO.2003.02.083
M. Adhyam y A. K. Gupta, “A Review on the Clinical Utility of PSA in Cancer Prostate”. Indian J Surg Oncol, vol. 3, no. 2, pp. 120-129, Jun. 2012. doi: 10.1007 / s13193-012-0142-6.
I. Hermida Lazcano, et ál., “Marcadores Tumorales”. Rev Clin Med Fam, vo. 9, no. 1, pp. 31-42, Feb. 2016.
E. Gregorio, et ál., “Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and 10 ng/m”. Int Braz J Urol. , vol. 33, no. 2, pp. 151-160, 2007. doi: 10.1590 / s1677-55382007000200004.
C. M. Sturgeon, et ál., “National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers”. Clin Chem, vol. 54, no. 12, pp. e11-79., Dic. 2008. doi: 10.1373 / clinchem.2008.105601.
M. Fabbri, “miRNAs as molecular biomarkers of cancer”. Expert Review of Molecular Diagnostics, vol. 10, no. 4, pp. 435-444, 2010. doi: 10.1586/erm.10.27
H. Lan, H. Lu, X. Wang, H. Jin, “MicroRNAs as potential biomarkers in cancer: opportunities and challenges”. BioMed Research International, vol. 2015, Article ID 125094, 2015. doi: 10.1155/2015/125094
P.J. Mishra, “MicroRNAs as promising biomarkers in cancer diagnostics”. Biomark Res, vol. 2, no. 19, 2014. doi: 10.1186/2050-7771-2-19
R. Ma, M. Zhao, X. Zou, J. Zhou and Z. Bai, “MicroRNA polymorphism: A target for diagnosis and prognosis of hepatocellular carcinoma? (Review)”. Oncol Lett., vol. 21, no. 4, 2021 doi: 10.3892/ol.2021.12586
A.C. Kölbl, K. Schlenk, N. Behrendt, U. Andergasse, “The importance of hcg in human endometrial adenocarcinoma and breast cancer”. International Journal of Biological Markers, vol 33, no. 1, pp. 33-39, 2018.
C. Haslam, S. Damiati, T. Whitley, P. Davey, E. Ifeachor, S. Awan, “Label-Free Sensors Based on Graphene Field-Effect Transistors for the Detection of Human Chorionic Gonadotropin Cancer Risk Biomarker”. Diagnostics, vol. 8, no. 1, 2018.
Z. Li, C. Li, L. Du, Y. Zhou, W. Wu, “Human Chorionic Gonadotropin β Induces Migration and Invasion via Activating ERK1/2 and MMP-2 in Human Prostate Cancer DU145 Cells”. PLoS ONE, vol. 8, no. 2, 2013.
R.K. Iles, P.J. Delves, S.A. Butler, “Does hCG or hCGβ play a role in cancer cell biology?” Molecular and Cellular Endocrinology, vol. 329, no. 1-2, pp. 62–70, 2010.
S.K. Sengodan, R. Nadhan, R.S. Nair, S.K. Hemalatha, V. Somasundaram, R.R. Sushama, et al., “BRCA1 regulation on β-hCG: A mechanism for tumorigenicity in BRCA1 defective breast cancer”. Oncogenesis, vol. 6, no. 9, 2017.
J.C. Marchán, “Gonadotropina coriónica humana, una hormona versátil y un marcador tumoral esencial en cáncer testicular de células germinales no seminomatosas”. Revista Colombiana de Endocrinología, Diabetes & Metabolismo, vol. 6, no. 2, pp. 107–113, 2019.
C. Nwabuobi, S. Arlier, F. Schatz, O. Guzeloglu-Kayisli, C.J. Lockwood, U.A. Kayisli, “hCG: Biological functions and clinical applications”. International Journal of Molecular Sciences, vol.18, no.10, pp. 1–15, 2017.
K. Mäbert, M. Cojoc, C. Peitzsch, I. Kurth, S. Souchelnytskyi, A. Dubrovska, “Cancer biomarker discovery: Current status and future perspectives”. International Journal of Radiation Biology. vol. 90, no.8, pp:659–77, 2014.
A. Mordente, E. Meucci, G.E. Martorana, A. Silvestrini, “Cancer biomarkers discovery and validation: State of the art, problems and future perspectives”. Advances in Experimental Medicine and Biology. pp: 9–26, 2015.
A. Kretschmer, D. Tilki, “Biomarkers in prostate cancer – Current clinical utility and future perspectives”. Critical Reviews in Oncology/Hematology, vol. 120, pp: 180–93, 2017.